Neurocrine Biosciences, Inc. $NBIX Stock Sold by Ellsworth Advisors LLC

Ellsworth Advisors LLC lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 94.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,040 shares of the company’s stock after selling 37,587 shares during the period. Ellsworth Advisors LLC’s holdings in Neurocrine Biosciences were worth $289,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of NBIX. NewEdge Advisors LLC boosted its stake in Neurocrine Biosciences by 0.5% in the 1st quarter. NewEdge Advisors LLC now owns 13,066 shares of the company’s stock worth $1,721,000 after buying an additional 68 shares during the last quarter. Westpac Banking Corp lifted its position in shares of Neurocrine Biosciences by 6.0% in the 1st quarter. Westpac Banking Corp now owns 1,615 shares of the company’s stock worth $213,000 after acquiring an additional 91 shares during the period. PKO Investment Management Joint Stock Co boosted its stake in shares of Neurocrine Biosciences by 7.7% in the 1st quarter. PKO Investment Management Joint Stock Co now owns 1,400 shares of the company’s stock valued at $184,000 after purchasing an additional 100 shares in the last quarter. Meiji Yasuda Life Insurance Co increased its position in Neurocrine Biosciences by 1.8% in the second quarter. Meiji Yasuda Life Insurance Co now owns 5,628 shares of the company’s stock worth $949,000 after purchasing an additional 100 shares during the period. Finally, SJS Investment Consulting Inc. lifted its stake in shares of Neurocrine Biosciences by 67.2% in the 1st quarter. SJS Investment Consulting Inc. now owns 341 shares of the company’s stock valued at $45,000 after purchasing an additional 137 shares during the period. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Leslie V. Norwalk sold 1,250 shares of the firm’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $182.01, for a total transaction of $227,512.50. Following the transaction, the director directly owned 1,588 shares of the company’s stock, valued at approximately $289,031.88. This trade represents a 44.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Matt Abernethy sold 2,311 shares of Neurocrine Biosciences stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $157.20, for a total value of $363,289.20. Following the sale, the chief financial officer owned 42,808 shares of the company’s stock, valued at approximately $6,729,417.60. This represents a 5.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 4,387 shares of company stock worth $720,855 in the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Stock Down 0.9%

NASDAQ NBIX opened at $135.71 on Friday. The business has a 50 day moving average price of $149.10 and a 200-day moving average price of $153.45. Neurocrine Biosciences, Inc. has a 52 week low of $122.14 and a 52 week high of $186.12. The company has a market cap of $13.79 billion, a price-to-earnings ratio of 19.90, a P/E/G ratio of 0.60 and a beta of 0.40.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Friday, July 31st. The company reported $2.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.65 by $1.20. The firm had revenue of $959.00 million during the quarter, compared to analyst estimates of $891.16 million. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The business’s revenue was up 39.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.65 EPS. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 7.70 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. BMO Capital Markets lowered their price target on shares of Neurocrine Biosciences from $164.00 to $150.00 and set a “market perform” rating for the company in a report on Monday, October 12th. UBS Group lowered their target price on shares of Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating on the stock in a report on Tuesday, September 29th. Wells Fargo & Company boosted their target price on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $204.00 target price on shares of Neurocrine Biosciences in a research note on Friday. Finally, Weiss Ratings upgraded Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $201.14.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and related disorders. The company is headquartered in San Diego, California, and conducts research through internal programs and collaborations with academic institutions and other pharmaceutical companies.

Neurocrine’s principal commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia and chorea associated with Huntington’s disease.